Skip to main content
Gland Pharma Limited logo

Gland Pharma Limited — Investor Relations & Filings

Ticker · GLAND ISIN · INE068V01023 LEI · 335800JJVDY5R6KF5K34 BSE.NS Manufacturing
Open in API
Filings indexed 676 across all filing types
Latest filing 2025-11-13 Regulatory Filings
Country IN India
Listing BSE.NS GLAND

About Gland Pharma Limited

https://glandpharma.com

Gland Pharma Limited is a specialized Contract Development and Manufacturing Organization (CDMO) focused on injectable formulations. The company operates primarily through a business-to-business (B2B) model, providing development and manufacturing services for a diverse range of sterile injectables. Its portfolio encompasses complex generics across various therapeutic areas, including oncology, ophthalmology, anti-infectives, and orthopedics. Gland Pharma maintains a vertically integrated supply chain, ensuring control over critical raw materials and active pharmaceutical ingredients. The company serves a global market, with a significant presence in regulated regions such as the United States, Europe, Canada, and Australia. Its manufacturing facilities adhere to international quality standards and hold approvals from major regulatory bodies. Key strengths include expertise in niche segments like heparin and enoxaparin, alongside a robust pipeline of complex delivery systems.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges notifying them of the schedule of upcoming analyst and institutional investor meetings. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulation 30, which mandates disclosure of material events including investor meetings. The document contains no financial data, no report content, and is relatively short (2187 characters). It is an announcement of scheduled meetings rather than a report or transcript of the meetings themselves. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2025-11-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is titled "Earnings call Transcript – Q2FY26" and contains a detailed transcript of the company's earnings conference call held on November 3, 2025. It includes management commentary, financial performance data for Q2 and H1 FY26, operational updates, and strategic outlook. The text is extensive (15,000 characters) and includes a full transcript of the call, not just an announcement or summary. There are no indications that this is a brief announcement or a report publication notice. The content matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A.
2025-11-07 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the publication of a newspaper advertisement for the unaudited financial results of the quarter and half year ended September 30, 2025. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure requirements. The document itself is not the financial results report but an announcement about the advertisement of these results. The document length is short (1363 characters), and it states that the advertisement is enclosed for information and records. Therefore, this is an announcement related to financial results publication, not the report itself. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement and does not contain substantive financial data or the full report.
2025-11-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the earnings call recording for the quarter and half year ended September 30, 2025. It mentions the date of the earnings call and provides a weblink to the audio recording. The document does not contain the transcript or detailed financial data but is an announcement about the availability of the earnings call recording. According to the classification rules, announcements about earnings calls or their recordings fall under Call Transcript (CT) if the full transcript is provided. However, since this document only announces the recording and provides a link without the transcript text, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement related to the earnings call but does not contain the transcript itself or financial data. The document length is short (1436 characters), supporting that it is an announcement rather than a full report or transcript.
2025-11-03 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation on Q2FY26 Financial Results' and is addressed to stock exchanges pursuant to SEBI regulations, indicating it is an official investor communication. It contains detailed financial highlights, including consolidated and segment-wise P&L data, margins, and business updates for Q2 FY26, with comparisons to prior quarters and years. The presence of forward-looking statements, safe harbour disclaimers, and detailed financial metrics typical of investor presentations further supports this classification. The document is approximately 15,000 characters long and contains substantive financial data and analysis, not merely an announcement or summary. Therefore, it fits the definition of an Investor Presentation (IP).
2025-11-03 English
Press Release
Interim / Quarterly Report Classification · 95% confidence The document is a press release dated November 3, 2025, announcing the Q2 FY26 financial results of Gland Pharma Limited. It contains detailed financial data including revenue, EBITDA, PAT, margins, and segment-wise performance for the quarter and half-year periods. The document includes management commentary on the results and business highlights such as R&D expenses, new product launches, and operational updates. The presence of comprehensive financial figures and analysis for a quarterly period indicates this is a financial results announcement. The document is not merely a brief summary or a notification of report publication but contains substantive financial data and management discussion. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2026
2025-11-03 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.